vs
GRIFFON CORP（GFF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是GRIFFON CORP的1.2倍（$772.1M vs $649.1M），Revvity净利率更高（12.7% vs 9.9%，领先2.8%），Revvity同比增速更快（5.9% vs 2.6%），Revvity自由现金流更多（$161.8M vs $99.3M），过去两年Revvity的营收复合增速更高（9.0% vs -1.8%）
格里芬公司是总部位于纽约的跨国多元化控股集团，业务覆盖多领域运营，旗下拥有Ames True Temper、ClosetMaid、Clopay建筑产品和CornellCookson四大子公司。该公司1961年起在纽交所公开上市，是标普小盘600指数、标普1500综合指数及罗素2000指数的成分股。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GFF vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$649.1M
营收增速更快
RVTY
高出3.2%
2.6%
净利率更高
RVTY
高出2.8%
9.9%
自由现金流更多
RVTY
多$62.5M
$99.3M
两年增速更快
RVTY
近两年复合增速
-1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $649.1M | $772.1M |
| 净利润 | $64.4M | $98.4M |
| 毛利率 | 41.1% | — |
| 营业利润率 | 17.5% | 14.5% |
| 净利率 | 9.9% | 12.7% |
| 营收同比 | 2.6% | 5.9% |
| 净利润同比 | -9.1% | 3.9% |
| 每股收益（稀释后） | $1.41 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GFFRVTY
| Q4 25 | $649.1M | $772.1M | ||
| Q3 25 | $662.2M | $698.9M | ||
| Q2 25 | $613.6M | $720.3M | ||
| Q1 25 | $611.7M | $664.8M | ||
| Q4 24 | $632.4M | $729.4M | ||
| Q3 24 | $659.7M | $684.0M | ||
| Q2 24 | $647.8M | $691.7M | ||
| Q1 24 | $672.9M | $649.9M |
净利润GFFRVTY
| Q4 25 | $64.4M | $98.4M | ||
| Q3 25 | $43.6M | $46.7M | ||
| Q2 25 | $-120.1M | $53.9M | ||
| Q1 25 | $56.8M | $42.2M | ||
| Q4 24 | $70.9M | $94.6M | ||
| Q3 24 | $62.5M | $94.4M | ||
| Q2 24 | $41.1M | $55.4M | ||
| Q1 24 | $64.1M | $26.0M |
毛利率GFFRVTY
| Q4 25 | 41.1% | — | ||
| Q3 25 | 41.7% | 53.6% | ||
| Q2 25 | 43.2% | 54.5% | ||
| Q1 25 | 41.2% | 56.5% | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 39.9% | 56.3% | ||
| Q2 24 | 38.5% | 55.7% | ||
| Q1 24 | 40.2% | 54.6% |
营业利润率GFFRVTY
| Q4 25 | 17.5% | 14.5% | ||
| Q3 25 | 18.0% | 11.7% | ||
| Q2 25 | -20.5% | 12.6% | ||
| Q1 25 | 16.5% | 10.9% | ||
| Q4 24 | 17.7% | 16.3% | ||
| Q3 24 | 16.9% | 14.3% | ||
| Q2 24 | 13.8% | 12.4% | ||
| Q1 24 | 16.9% | 6.8% |
净利率GFFRVTY
| Q4 25 | 9.9% | 12.7% | ||
| Q3 25 | 6.6% | 6.7% | ||
| Q2 25 | -19.6% | 7.5% | ||
| Q1 25 | 9.3% | 6.4% | ||
| Q4 24 | 11.2% | 13.0% | ||
| Q3 24 | 9.5% | 13.8% | ||
| Q2 24 | 6.3% | 8.0% | ||
| Q1 24 | 9.5% | 4.0% |
每股收益（稀释后）GFFRVTY
| Q4 25 | $1.41 | $0.86 | ||
| Q3 25 | $1.04 | $0.40 | ||
| Q2 25 | $-2.65 | $0.46 | ||
| Q1 25 | $1.21 | $0.35 | ||
| Q4 24 | $1.49 | $0.77 | ||
| Q3 24 | $1.29 | $0.77 | ||
| Q2 24 | $0.84 | $0.45 | ||
| Q1 24 | $1.28 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $95.3M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $108.9M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GFFRVTY
| Q4 25 | $95.3M | $919.9M | ||
| Q3 25 | $99.0M | $931.4M | ||
| Q2 25 | $107.3M | $991.8M | ||
| Q1 25 | $127.8M | $1.1B | ||
| Q4 24 | $152.0M | $1.2B | ||
| Q3 24 | $114.4M | $1.2B | ||
| Q2 24 | $133.5M | $2.0B | ||
| Q1 24 | $123.0M | $1.7B |
总债务GFFRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.6B | — |
股东权益GFFRVTY
| Q4 25 | $108.9M | $7.3B | ||
| Q3 25 | $74.0M | $7.4B | ||
| Q2 25 | $63.9M | $7.6B | ||
| Q1 25 | $214.7M | $7.6B | ||
| Q4 24 | $227.8M | $7.7B | ||
| Q3 24 | $224.9M | $7.9B | ||
| Q2 24 | $223.5M | $7.9B | ||
| Q1 24 | $202.2M | $7.8B |
总资产GFFRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.3B | $12.4B | ||
| Q4 24 | $2.3B | $12.4B | ||
| Q3 24 | $2.4B | $12.8B | ||
| Q2 24 | $2.4B | $13.4B | ||
| Q1 24 | $2.4B | $13.4B |
负债/权益比GFFRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 22.71× | — | ||
| Q1 25 | 7.16× | — | ||
| Q4 24 | 6.48× | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 6.74× | — | ||
| Q1 24 | 7.84× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $107.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $99.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 15.3% | 21.0% |
| 资本支出强度资本支出/营收 | 1.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.66× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $278.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GFFRVTY
| Q4 25 | $107.0M | $182.0M | ||
| Q3 25 | $75.0M | $138.5M | ||
| Q2 25 | $123.1M | $134.3M | ||
| Q1 25 | $16.5M | $128.2M | ||
| Q4 24 | $142.9M | $174.2M | ||
| Q3 24 | $72.1M | $147.9M | ||
| Q2 24 | $122.1M | $158.6M | ||
| Q1 24 | $39.8M | $147.6M |
自由现金流GFFRVTY
| Q4 25 | $99.3M | $161.8M | ||
| Q3 25 | $62.4M | $120.0M | ||
| Q2 25 | $114.4M | $115.5M | ||
| Q1 25 | $2.8M | $112.2M | ||
| Q4 24 | $125.5M | $149.8M | ||
| Q3 24 | $51.6M | $125.6M | ||
| Q2 24 | $107.5M | $136.6M | ||
| Q1 24 | $20.8M | $129.7M |
自由现金流率GFFRVTY
| Q4 25 | 15.3% | 21.0% | ||
| Q3 25 | 9.4% | 17.2% | ||
| Q2 25 | 18.6% | 16.0% | ||
| Q1 25 | 0.5% | 16.9% | ||
| Q4 24 | 19.8% | 20.5% | ||
| Q3 24 | 7.8% | 18.4% | ||
| Q2 24 | 16.6% | 19.7% | ||
| Q1 24 | 3.1% | 20.0% |
资本支出强度GFFRVTY
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | 2.8% | 3.4% | ||
| Q3 24 | 3.1% | 3.3% | ||
| Q2 24 | 2.2% | 3.2% | ||
| Q1 24 | 2.8% | 2.7% |
现金转化率GFFRVTY
| Q4 25 | 1.66× | 1.85× | ||
| Q3 25 | 1.72× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 0.29× | 3.03× | ||
| Q4 24 | 2.02× | 1.84× | ||
| Q3 24 | 1.15× | 1.57× | ||
| Q2 24 | 2.97× | 2.87× | ||
| Q1 24 | 0.62× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GFF
| Consumer And Professional Products | $241.1M | 37% |
| Residential Repairand Remodel | $202.1M | 31% |
| International Excluding North America | $97.8M | 15% |
| Retail | $47.3M | 7% |
| Residential New Construction | $32.5M | 5% |
| Other | $14.2M | 2% |
| Industrial | $14.1M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
